HK Stock Market Move | XTALPI-P(02228) rose by over 6% again, the AI pharmaceutical field continues to thrive, and the industry is expected to enter a stage of "qualitative change".

XTALPI-P (02228) rose more than 6%, as of the time of writing, it increased by 6.27% to HK$7.12 with a turnover of HK$269 million. Guotou Securities released a research report stating that in recent years, the AI pharmaceutical sector has continued to thrive due to the increasing demand for accelerated drug development, expansion in the AI application field, and support from related policies. According to ResearchAndMarkets data, the global AI pharmaceutical market size is expected to increase from USD 792 million in 2021 to USD 1.758 billion in 2024. With the improvement in success rates of AI-led drug development projects and continuous progress in related research pipelines, the further commercialization of AI pharmaceutical technology is promising. Haitong previously pointed out that from the early exploration in 2007 to now, AI pharmaceutical technology has undergone stages of technological accumulation, validation, and rapid development, and it is currently in a phase of active technological innovation, evident policy support, and broad market prospects. The application of AI pharmaceutical technology is expected to shorten the drug development cycle, reduce costs, and increase success rates in research and development. AI technology makes the entire process from drug design to clinical trials more efficient, bringing innovative changes to traditional drug development, demonstrating vast prospects and tremendous potential in the field of drug research and development. With the continuous advancement of AI technology and the enhancement of CRO companies' professional capabilities, the future drug research and development field is expected to see more innovative breakthroughs.